Evaluation on efficacy and safety of capecitabine plus docetaxel versus docetaxel monotherapy in metastatic breast cancer patients pretreated with anthracycline: Results from a randomized phase III study (JO21095)

Trial Profile

Evaluation on efficacy and safety of capecitabine plus docetaxel versus docetaxel monotherapy in metastatic breast cancer patients pretreated with anthracycline: Results from a randomized phase III study (JO21095)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 17 Jan 2013

At a glance

  • Drugs Capecitabine (Primary) ; Docetaxel
  • Indications Advanced breast cancer
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 17 Jan 2013 New trial record
    • 08 Dec 2012 Analysis of the overall survival data is under examination according to the abstract presented at the 35th Annual San Antonio Breast Cancer Symposium.
    • 08 Dec 2012 Results of an analysis on the effect of circulating tumour cells on response were presented at the 35th Annual San Antonio Breast Cancer Symposium.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top